Rachna T Shroff, MD, MS, FASCO | Cancer ...

Dr. Rachna Shroff, M.D.

Claim this profile

University of Arizona Cancer Center

Studies Pancreatic Cancer
Studies Liver Cancer
15 reported clinical trials
33 drugs studied

Area of expertise

1Pancreatic Cancer
Rachna Shroff, M.D. has run 5 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
metastatic
RECIST 1.1
2Liver Cancer
Rachna Shroff, M.D. has run 4 trials for Liver Cancer. Some of their research focus areas include:
Stage IV
Stage III
MSI

Affiliated Hospitals

Image of trial facility.
University Of Arizona Cancer Center
Image of trial facility.
Banner University Medical Center - Tucson

Clinical Trials Rachna Shroff, M.D. is currently running

Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting4 awards Phase 318 criteria
Image of trial facility.

Atezolizumab + Cabozantinib

for Pancreatic Cancer

Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive combination cabozantinib + atezolizumab and the efficacy of this treatment will be assessed through overall response rate (ORR), disease control rate (DCR), median overall survival (mOS), and median progression free survival (mPFS). Safety and tolerability of combination cabozantinib plus atezolizumab in metastatic pancreatic cancer patients will also be assessed and immune profiling pre- and post-treatment will be explored.
Recruiting1 award Phase 212 criteria

More about Rachna Shroff, M.D.

Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Rachna Shroff, M.D. has experience with
  • Gemcitabine
  • Cisplatin
  • Oxaliplatin
  • LSTA1
  • Cabozantinib
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Rachna Shroff, M.D. specialize in?
Is Rachna Shroff, M.D. currently recruiting for clinical trials?
Are there any treatments that Rachna Shroff, M.D. has studied deeply?
What is the best way to schedule an appointment with Rachna Shroff, M.D.?
What is the office address of Rachna Shroff, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security